Title : Personalized and precision medicine (PPM) as the unique healthcare model to secure the national health and wellness: From family planning and gestation period and neonatology through human biosafety

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized & precision medicine (PPM). PPM as being the Grand Challenge to forecast, to predict and to prevent is rooted in a big and a new science generated by the achievements of systems biology and translational medicine, whilst integrating platforms of OMICS- and IT-technologies.

NIH (Bethesda, MD, USA) have The Unique Decision had on setting up in USA a Clinical Research Network including Centers of PPM, Centers for Personalized & Precision Pediatrics (CPPP) and Reproductive Precision Medicine Centers (RPMC, e.g., at Columbia University).

The concept of PPM and RPMC has been applied in reproductive medicine long before its popularization.

One of the well-known uses of PPM-related resources in reproductive medicine and family planning is the genetic test that most accurately determines how receptive a woman’s endometrium (inner uterine lining) is for implanting an embryo. Perhaps what is currently being offered as personalized treatment of infertile patient is more based on “the best expert opinion of the attending clinician” than “the best evidence-based data available”. In this sense, The Columbia University Reproductive Precision Medicine Center is perfectly positioned to be a global leader in the development and implementation of these approaches. PPM and personalized and precision genomics as the major part of the Reproductive medicine & Family planning are a new and exciting field with the potential to significantly improve medical care for pregnant women and newborns.

In general, four major types of genomic biomarkers are crucially important and valuable for PPM-related services: Diagnostic, Predictive, Monitoring and Prognostic ones, to be used in most of genomic testing platforms. Among the testing panels are: Carrier testing, Pre-symptomatic & Predictive Testing, Pre-conception testing, Newborn testing, Prenatal testing (NIPT), Nutriogenomic and Pharmacogenomic testing.

The use of genomic profiling for prenatal diagnosis of fetuses with sonographic abnormalities has grown tremendously over the past decade. By tuning into your body’s natural rhythms, these precision methods empower you to make informed decisions regarding conception - or its prevention, often in consultation with your obstetrician.

Improved patient (or persons-at-risk) outcomes must consider not only increased survival, or quality of life, but also improved clinical decision support (CDS) & making! Each decision-maker values the impact of their decision to use PPM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to provide more tailored measures for the patients resulting in improved patient outcomes, reduced adverse events, and more cost effective use of health care resources.

The application of PPM has become a guideline for the development of medicine, especially for reproductive medicine, family planning and neonatology.

PPM in reproductive health involves using an individual’s genetic and biological information to design customized treatment plans for fertility and related conditions.

In pediatrics, PPM approach is particularly crucial because children are not simply “small adults” and often display different disease symptoms, responses to medication, and recovery patterns than adults. The application of PPM in pediatrics has shown encouraging results in oncology, where genetic profiling of tumors can guide the selection of targeted therapies, thus improving outcomes. PPM is also expanding into other pediatric therapeutic areas such as neurology, where genetic insights into epilepsy or autism spectrum disorders are facilitating personalized therapeutic strategies. Respiratory and infectious diseases are yet more fields where PPM approaches are being studied to tailor treatments according to patient-specific immune responses and microbiomes. Moreover, the pediatric population is not only distinct from the adult population, but also heterogeneous due to physiologic and developmental differences. Thus, the success of pediatric PPM relies on both an understanding of this heterogeneity and availability of validated biomarkers and assays to revolutionize pediatric healthcare by making it more preventive and personalized.

PPM is transforming the landscape of Family Planning, Neonatology and Reproductive Medicine as a whole, offering tailored approaches to care that enhance patient outcomes. From genetic screening and counseling to PPM-guided oncology and hormonal therapies, PPM has the potential to revolutionize women’s and offspring healthcare. However, successful implementation requires collaboration among healthcare providers, geneticists, biodesigners and researchers, alongside continued advancements in technology and ethical frameworks. By embracing PPM, reproductive medicine, family planning and neonatology can pave the way for a future where women receive individualized, evidence-based care, leading to improved health and well-being.

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Med University and was awarded with MD. In 1985, maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Inst of Med Enzymology. In 2001, maintained his Doctor Degree at the Nat Inst of Immunology, Russia.

From 1989 through 1995, was being a Head of the Lab of Clin Immunology, Helmholtz Eye Research Inst in Moscow. From 1995 through 2004 - a Chair of the Dept for Clin Immunology, Moscow Clinical Research Institute (MONIKI). In 1993-1996, was a Secretary-in-Chief of the Edit Board, Biomedical Science, an int journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.

At present, Dr Sergey Suchkov, MD, PhD, is:

•  Professor in Medicine & Immunology and Director for Center for Biodesign, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Moscow, Russia
• ● R&D Director, InMedStar, Russia-UAE
• ● Senior Scientific Advisor of China Hong Kong Innovation International Business Association, Hong Kong
• ● The Russian Academy of Natural Sciences, Moscow, Russia

Dr Suchkov is a member of the:

• The Russian Academy of Natural Sciences, Moscow, Russia
• New York Academy of Sciences, USA
• American Chemical Society (ACS), USA;
• American Heart Association (AHA), USA;
• European Association for Medical Education (AMEE), Dundee, UK;
• EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU;
• ARVO (American Association for Research in Vision and Ophthalmology);
• ISER (International Society for Eye Research);
• Personalized Medicine Coalition (PMC), Washington, DC, USA